$ファソム ファーマシューティカルズ(PHAT.US)$NEWS SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT SynOx Therapeutics has closed a $75m Series B financing round led by Forbion, HealthCap, and Bioqube Ventures to fund a Phase 3 trial of emactuzumab, a potential best-in-class treatment for Tenosynovial Giant Cell Tumour (TGCT). Emactuzumab has shown promising clinical activity with a 71% objective response rate and good tolerability in earl...
Insider share sales at Phathom Pharmaceuticals in the last three months are not substantial but still concerning. The level of insider ownership shows some alignment with smaller shareholders. However, 6 warning signs, 3 of which are concerning, should be noted by investors.
$ファソム ファーマシューティカルズ(PHAT.US)$The FDA has assigned the application a standard 10-month review with a PDUFA target action date of July 19, 2024. The company is also finalizing its plans to initiate an additional Phase 3 study in 2024 evaluating VOQUEZNA as an investigational As Needed treatment for episodic heartburn relief in adults with Non-Erosive GERD
$ファソム ファーマシューティカルズ(PHAT.US)$Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD 3 MINUTES AGO, 8:00 AM EST VIA GLOBENEWSWIRE
$ファソム ファーマシューティカルズ(PHAT.US)$Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GER
Insider selling at Phathom Pharmaceuticals has recently escalated. Yet, insiders' net purchase over the past year, holding a hefty stake, suggests confidence in the future.
ファソム ファーマシューティカルズに関するコメント
SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT
SynOx Therapeutics has closed a $75m Series B financing round led by Forbion, HealthCap, and Bioqube Ventures to fund a Phase 3 trial of emactuzumab, a potential best-in-class treatment for Tenosynovial Giant Cell Tumour (TGCT). Emactuzumab has shown promising clinical activity with a 71% objective response rate and good tolerability in earl...
The company is also finalizing its plans to initiate an additional Phase 3 study in 2024 evaluating VOQUEZNA as an investigational As Needed treatment for episodic heartburn relief in adults with Non-Erosive GERD
まだコメントはありません